BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30786111)

  • 1. Blastemal predominant type Wilms tumor in Japan: Japan Children's Cancer Group.
    Koshinaga T; Takimoto T; Okita H; Tanaka Y; Inoue E; Oue T; Nozaki M; Tsuchiya K; Haruta M; Kaneko Y; Fukuzawa M
    Pediatr Int; 2019 Apr; 61(4):351-357. PubMed ID: 30786111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic significance of blastemal predominant histology in initially resected Wilms' tumors: a report from the Study Group for Pediatric Solid Tumors in the Kyushu Area, Japan.
    Kinoshita Y; Suminoe A; Inada H; Yagi M; Yanai F; Zaizen Y; Nishi M; Inomata Y; Kawakami K; Matsufuji H; Suenobu S; Handa N; Kohashi K; Oda Y; Hara T; Taguchi T
    J Pediatr Surg; 2012 Dec; 47(12):2205-9. PubMed ID: 23217877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of renal tumors registered in Japan Wilms Tumor Study-2 (JWiTS-2): A report from the Japan Children's Cancer Group (JCCG).
    Koshinaga T; Takimoto T; Oue T; Okita H; Tanaka Y; Nozaki M; Tsuchiya K; Inoue E; Haruta M; Kaneko Y; Fukuzawa M
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27056. PubMed ID: 29630767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapse of unilateral favorable histology Wilms' tumor: significant clinicopathological factors.
    Aoba T; Urushihara N; Fukumoto K; Furuta S; Fukuzawa H; Mitsunaga M; Watanabe K; Yamoto M; Miyake H; Koyama M; Iwabuchi H; Koike J; Tatsunami S; Wakisaka M; Kitagawa H
    J Pediatr Surg; 2012 Dec; 47(12):2210-5. PubMed ID: 23217878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognosis of prechemotherapy blastemal predominant histology subtype in Wilms tumor: A retrospective study in China.
    Huang J; Zhang Y; Zhen Z; Lu S; Zhu J; Wang J; Sun F; Liu Z; Gao Y; Li H; Zhang Y; Sun X
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28567. PubMed ID: 32813315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is radiotherapy required in first-line treatment of stage I diffuse anaplastic Wilms tumor? A report of SIOP-RTSG, AIEOP, JWiTS, and UKCCSG.
    Fajardo RD; van den Heuvel-Eibrink MM; van Tinteren H; Spreafico F; Acha T; Bergeron C; de Camargo B; Oldenburger F; Rübe C; Oue T; Vokuhl C; de Krijger RR; Vujanic G; Sebire N; Coulomb-L'Hermine A; Collini P; Gandola L; Pritchard-Jones K; Graf N; Janssens GO; van Grotel M
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28039. PubMed ID: 31625685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
    Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
    Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anaplastic histology Wilms' tumors registered to the Japan Wilms' Tumor Study Group are less aggressive than that in the National Wilms' Tumor Study 5.
    Oue T; Koshinaga T; Takimoto T; Okita H; Tanaka Y; Nozaki M; Haruta M; Kaneko Y; Fukuzawa M;
    Pediatr Surg Int; 2016 Sep; 32(9):851-5. PubMed ID: 27473009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG).
    van den Heuvel-Eibrink MM; van Tinteren H; Bergeron C; Coulomb-L'Hermine A; de Camargo B; Leuschner I; Sandstedt B; Acha T; Godzinski J; Oldenburger F; Gooskens SL; de Kraker J; Vujanic GM; Pritchard-Jones K; Graf N
    Eur J Cancer; 2015 Mar; 51(4):498-506. PubMed ID: 25592561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blastemal NCAM
    Raved D; Tokatly-Latzer I; Anafi L; Harari-Steinberg O; Barshack I; Dekel B; Pode-Shakked N
    Pathol Res Pract; 2019 Aug; 215(8):152491. PubMed ID: 31202518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of TCF3 as potential master regulator in blastemal Wilms tumors.
    Kehl T; Schneider L; Kattler K; Stöckel D; Wegert J; Gerstner N; Ludwig N; Distler U; Tenzer S; Gessler M; Walter J; Keller A; Graf N; Meese E; Lenhof HP
    Int J Cancer; 2019 Mar; 144(6):1432-1443. PubMed ID: 30155889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity.
    Weirich A; Ludwig R; Graf N; Abel U; Leuschner I; Vujanic GM; Mehls O; Boos J; Beck J; Royer-Pokora B; Voûte PA
    Ann Oncol; 2004 May; 15(5):808-20. PubMed ID: 15111352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of nuclear unrest and p53 immunostaining in Wilms' tumor.
    Salama A; Kamel A
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):31-9. PubMed ID: 22099934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors responsible for stage III disease in patients with Wilms tumor enrolled in the JWiTS-2 study.
    Oue T; Fukumoto K; Souzaki R; Takimoto T; Koshinaga T;
    Pediatr Surg Int; 2019 Oct; 35(10):1095-1099. PubMed ID: 31396736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilateral Wilms tumors treated according to the Japan Wilms Tumor Study Group protocol.
    Oue T; Koshinaga T; Okita H; Kaneko Y; Hinotsu S; Fukuzawa M
    Pediatr Blood Cancer; 2014 Jul; 61(7):1184-9. PubMed ID: 24623612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and prognostic value Of CD44 isoforms in nephroblastoma (Wilms tumor).
    Ghanem MA; Van Steenbrugge GJ; Van Der Kwast TH; Sudaryo MK; Noordzij MA; Nijman RJ
    J Urol; 2002 Aug; 168(2):681-6. PubMed ID: 12131349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Teratoid" Wilms Tumor: The Extreme End of Heterologous Element Differentiation, Not a Separate Entity.
    D'Hooghe E; Mifsud W; Vujanić GM
    Am J Surg Pathol; 2019 Nov; 43(11):1583-1590. PubMed ID: 31600178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of patients with stage IV high-risk Wilms tumour treated according to the SIOP2001 protocol: A report of the SIOP Renal Tumour Study Group.
    Pasqualini C; Furtwängler R; van Tinteren H; Teixeira RAP; Acha T; Howell L; Vujanic G; Godzinski J; Melchior P; Smets AM; Coulomb-L'Hermine A; Brisse H; Pritchard-Jones K; Bergeron C; de Camargo B; van den Heuvel-Eibrink MM; Graf N; Verschuur AC
    Eur J Cancer; 2020 Mar; 128():38-46. PubMed ID: 32109849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of pediatric renal tumor treated using the Japan Wilms Tumor Study-1 (JWiTS-1) protocol: a report from the JWiTS group.
    Oue T; Fukuzawa M; Okita H; Mugishima H; Horie H; Hata J; Saito M; Nozaki M; Chin M; Nakadate H; Hinotsu S; Koshinaga T; Kaneko Y; Kitano Y; Tanaka Y;
    Pediatr Surg Int; 2009 Nov; 25(11):923-9. PubMed ID: 19701757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SIX1 protein expression selectively identifies blastemal elements in Wilms tumor.
    Sehic D; Karlsson J; Sandstedt B; Gisselsson D
    Pediatr Blood Cancer; 2012 Jul; 59(1):62-8. PubMed ID: 22180226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.